Skip to main content
SpringerLink
Log in

Screening for hypercoagulable syndromes following stroke

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

Patients with ischemic stroke of unclear etiology are often screened for hypercoagulable syndromes or thrombophilias. These have been recognized to cause venous thrombosis, and include hereditary deficiencies of coagulation factors, genetic mutations, or acquired disorders. However, the majority of coagulation disorders are only rarely associated with ischemic stroke. The tests most commonly used to screen for thrombophilias comprise a complex array of assays that may be unreliable in various settings, including acute thrombosis, inflammation, and uses of medications such as anticoagulants. The diagnostic yield of thrombophilia tests in unselected stroke patients is very low, but may improve with careful selection of younger patients who have an otherwise undetermined cause of stroke or a history of venous thrombosis or multiple miscarriages. Various strategies have been developed that can guide the selection of patients (based on specific characteristics) and tests in the evaluation of thrombophilias. Although the diagnosis of thrombophilia aids in the potential explanation of stroke etiology, the best regimen for secondary prevention treatment for the majority of thrombophilias is still unknown.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. American Heart Association: Heart Disease and Stroke Statistics—2003 Update. http://www.americanheart.org. Accessed on February 3, 2003.

  2. Sacco RL, Ellenberg JH, Mohr JP, et al.: Infarcts of undetermined cause: the NINCDS Stroke Data Bank. Ann Neurol 1989, 25:382–390.

    Article  PubMed  CAS  Google Scholar 

  3. Bushnell CD, Goldstein LB: Diagnostic testing for coagulopathies in patients with ischemic stroke. Stroke 2000, 31:3067–3078.

    PubMed  CAS  Google Scholar 

  4. Hankey GJ, Eikelboom JW, van Bockxmeer FM, et al.: Inherited thrombophilia in ischemic stroke and its pathogenic subtypes. Stroke 2001, 32:1793–1799.

    PubMed  CAS  Google Scholar 

  5. Juul K, Tybjaerg-Hansen A, Steffensen R, et al.: The Copenhagen City Heart Study and 2 meta-analyses. Blood 2002, 100:3–10.

    Article  PubMed  CAS  Google Scholar 

  6. Vandenbroucke JP, Koster T, Reitsma PH, et al.: Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994, 344:1453–1457.

    Article  PubMed  CAS  Google Scholar 

  7. Martinelli I, Landi G, Merati G, et al.: Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996, 75:393–394.

    PubMed  CAS  Google Scholar 

  8. Zuber M, Toulon P, Marnet L, Mas JL: Factor V Leiden mutation in cerebral venous thrombosis. Stroke 1996, 27:1721–1723.

    PubMed  CAS  Google Scholar 

  9. Salomon O, Steinberg D, Zivelin A, et al.: Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Biol 1999, 19:511–518.

    CAS  Google Scholar 

  10. Szolnoki Z, Somogyvari F, Kondacs A, et al.: Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke. J Neurol 2001, 248:756–761.

    Article  PubMed  CAS  Google Scholar 

  11. Seligsohn U, Lubetsky A: Medical progress: genetic susceptibility to venous thrombosis. N Engl J Med 2001, 344:1222–1231.

    Article  PubMed  CAS  Google Scholar 

  12. Longstreth WT Jr, Rosendaal FR, Siscovick DS, et al.: Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998, 29:577–580.

    PubMed  Google Scholar 

  13. Pezzini A, Del Zotto E, Magoni M, et al.: Inherited thrombophilic diosrders in young adults with ischemic stroke and patient foramen ovale. Stroke 2003, 34:28–33.

    Article  PubMed  Google Scholar 

  14. Kelly P, Rosand J, Kistler J, et al.: Homocysteine, MTHFR 677C → T polymorphism, and risk of ischemic stroke. Results of a meta-analysis. Neurology 2002, 59:529–536.

    PubMed  CAS  Google Scholar 

  15. Eikelboom JW, Lonn E, Genest J, et al.: Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999, 131:363–375.

    PubMed  CAS  Google Scholar 

  16. Ray J: Meta-analysis of hyperhomocysteinemia as a risk factor for deep-vein thrombosis. Arch Intern Med 1998, 158:2101–2106.

    Article  PubMed  CAS  Google Scholar 

  17. Madonna P, de Stefano V, Coppola A, et al.: Hyperhomocysteinemia and other inherited prothrombotic conditions in young adults with a history of ischemic stroke. Stroke 2002, 33:51–56.

    Article  PubMed  CAS  Google Scholar 

  18. Margaglione M, DiMinno G, Grandone E, et al.: Plasma lipoprotein(a) levels in subjects attending a metabolic ward: discrimination between individuals with and without a history of ischemic stroke. Arterioscler Thromb Biol 1996, 16:120–128.

    CAS  Google Scholar 

  19. van Kooten F, van Krimpen J, Dippel DW, et al.: Lipoprotein(a) in patients with acute cerebral ischemia. Stroke 1996, 27:1231–1235.

    PubMed  Google Scholar 

  20. Nagayama M, Shinohara Y, Nagayama T: Lipoprotein(a) and ischemic cerebrovascular disease in young adults. Stroke 1994, 25:74–78.

    PubMed  CAS  Google Scholar 

  21. Ridker PM, Stampfer MJ, Hennekens CH: Plasma concentration of lipoprotein(a) and the risk of future stroke. JAMA 1995, 273:1269–1273.

    Article  PubMed  CAS  Google Scholar 

  22. Milionis HJ, Winder AF, Mikhailidis DP: Lipoprotein (a) and stroke. J Clin Pathol 2000, 53:487–496.

    Article  PubMed  CAS  Google Scholar 

  23. Dahlen GH: Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis 1994, 108:111–126.

    Article  PubMed  CAS  Google Scholar 

  24. Etingin O, Hajjar D, Hajjar K, et al.: Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells: a potential mechanism in thrombogenesis. J Biol Chem 1991, 288:2459–2465.

    Google Scholar 

  25. Finazzi G, Brancaccio V, Moia M, et al.: Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. Am J Med 1996, 100:530–536.

    Article  PubMed  CAS  Google Scholar 

  26. Wilson WA, Gharavi AE, Koike T, et al.: International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 1999, 42:1309–1311.

    Article  PubMed  CAS  Google Scholar 

  27. Brey RL, Escalante A: Neurological manifestations of antiphospholipid antibody syndrome. Lupus 1998, 7(suppl 2):S67-S74.

    PubMed  Google Scholar 

  28. Rosove MH, Brewer PM: Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992, 117:303–308.

    PubMed  CAS  Google Scholar 

  29. The Antiphospholipid Antibodies in Stroke Study (APASS) Group: Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 1993, 43:2069–2073.

    Google Scholar 

  30. Tuhrim S, Rand JH, Wu XX, et al.: Elevated anticardiolipin antibody titer is a stroke risk factor in a multiethnic population independent of isotype or degree of positivity. Stroke 1999, 30:1561–1565.

    PubMed  CAS  Google Scholar 

  31. Tanne D, D’Olhaberriague L, Trivedi AM, et al.: Anticardiolipin antibodies and mortality in patients with ischemic stroke: A prospective follow-up study. Neuroepidemiology 2002, 21:93–99.

    Article  PubMed  Google Scholar 

  32. Heinzlef O, Abuaf N, Cohen A, Amarenco P: Recurrent stroke and vascular events in elderly patients with anticardiolipin antibodies: a prospective study. J Neurol 2001, 248:373–379.

    Article  PubMed  CAS  Google Scholar 

  33. Brey RL, Abbott RD, Curb JD, et al.: b2-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction. The Honolulu Heart Program. Stroke 2001, 32:1701–1706.

    PubMed  CAS  Google Scholar 

  34. Pierangeli SA, Stewart M, Silva LK, Harris EN: An antiphospholipid wet workshop: 7th international symposium on antiphospholipid antibodies. J Rheum 1998, 25:156–160.

    PubMed  CAS  Google Scholar 

  35. Muir KW, Squire IB, Alwan W, Lees KR: Anticardiolipin antibodies in an unselected stroke population. Lancet 1994, 344:452–456.

    Article  PubMed  CAS  Google Scholar 

  36. Horbach DA, von Oort E, Donders RC, et al.: Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996, 76:916–924.

    PubMed  CAS  Google Scholar 

  37. Nojima J, Suehisa E, Akita N, et al.: Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant. Br J Haematol 1997, 96:447–450.

    Article  PubMed  CAS  Google Scholar 

  38. Levine SR, Brey RL, Sawaya KL, et al.: Recurrent stroke and thrombo-occlusive events in the antiphospholipid syndrome. Ann Neurol 1995, 38:119–124.

    Article  PubMed  CAS  Google Scholar 

  39. Khamashta MA, Cuadrado MJ, Mujic F, et al.: The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995, 332:993–997.

    Article  PubMed  CAS  Google Scholar 

  40. Bushnell CD, Siddiqi Z, Morgenlander JC, Goldstein LB: Use of specialized coagulation testing in the evaluation of patients with acute ischemic stroke. Neurology 2001, 56:624–627.

    PubMed  CAS  Google Scholar 

  41. Bushnell CD, Siddiqi Z, Goldstein LB: Improving patient selection for specialized coagulation testing in the setting of acute ischemic stroke. Neurology 2001, 57:1333–1335.

    PubMed  CAS  Google Scholar 

  42. Comp PC: Laboratory evaluation of protein S status. Sem Thromb Hemost 1990, 16:177–181.

    Article  CAS  Google Scholar 

  43. Mayer SA, Sacco RL, Hurlet-Jensen A, et al.: Free protein S deficiency in acute ischemic stroke. A case-control study. Stroke 1993, 24:224–227.

    PubMed  CAS  Google Scholar 

  44. Triplett DA: Antiphospholipid antibodies and thrombosis. A consequence, coincidence, or cause? Arch Pathol Lab Med 1993, 117:78–88.

    PubMed  CAS  Google Scholar 

  45. Tanne D, D’Olhaberriague L, Schultz LR, et al.: Anticardiolipin antibodies and their associations with cerebrovascular risk factors. Neurology 1999, 52:1368–1373.

    PubMed  CAS  Google Scholar 

  46. Stampfer MJ, Malinow MR, Willett WC, et al.: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268:877–881.

    Article  PubMed  CAS  Google Scholar 

  47. Craig W, Ledue T: Lipoprotein(a) and the acute phase response. Clin Chim Acta 1992, 210:231–232.

    Article  PubMed  CAS  Google Scholar 

  48. Sackett DL, Haynes RB, Guyatt GH, Tugwell P: Clinical Epidemiology. In A Basic Science for Clinical Medicine, edn 2. Boston: Little, Brown, and Company; 1991.

    Google Scholar 

  49. Bushnell CD, Goldstein LB: Homocysteine testing in patients with acute ischemic stroke. Neurology 2002, 59:1541–1546.

    Article  PubMed  CAS  Google Scholar 

  50. Jacques PF, Rosenberg IH, Rogers F, et al.: Serum total homocysteine concentrations in adolescent and adult Americans: result from the third National Health and Nutrition Examination Survey. Am J Clin Nutr 1999, 69:482–489.

    PubMed  CAS  Google Scholar 

  51. Bushnell CD, Goldstein LB: Physician knowledge and practices in the evaluation of coagulopathies in stroke patients. Stroke 2002, 33:948–953.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Duke Center for Cerebrovascular Disease, Department of Medicine (Neurology), Duke University Medical Center, Box 2900, 27710, Durham, NC, USA

    Cheryl Bushnell MD, MHS & Larry B. Goldstein MD

Authors
  1. Cheryl Bushnell MD, MHS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larry B. Goldstein MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bushnell, C., Goldstein, L.B. Screening for hypercoagulable syndromes following stroke. Curr Atheroscler Rep 5, 291–298 (2003). https://doi.org/10.1007/s11883-003-0052-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-003-0052-8

Keywords

Search

Navigation